Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to intimation dated 4th April 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at Patalganga manufacturing facility, Cipla has informed that the United States Food and Drug Administration (USFDA) vide communication dated Tuesday, 25th June 2024 (12:37 AM IST) has classified the above referred inspection as Voluntary Action Indicated (VAI).
The above information is a part of company’s filings submitted to BSE.
